Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00384904 · ClinicalTrials.gov registry record · Phase 4
Drug Interaction Study of Famotidine and Atazanavir With Ritonavir in HIV-Infected Patients
A Phase 4 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
NCT00384904 is a Phase 4 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 40 participants.
The verdict
NCT00384904, a Phase 4 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this clinical research study is to assess the effect of Famotidine given twice daily on Atazanavir administered with Ritonavir in HIV-Infected subjects.
Interventions
- DRUG Atazanavir/Ritonavir
- DRUG Atazanavir/Ritonavir + Famotidine
- DRUG Atazanavir/Ritonavir + Tenofovir Disproxil Fumrarate + Famotidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2006-12 |
| Est. Completion | 2007-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00384904
The ClinicalTrials.gov registry entry for NCT00384904 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Atazanavir/Ritonavir is the first listed.
NCT00384904 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00384904 about?
NCT00384904 is a clinical study titled "Drug Interaction Study of Famotidine and Atazanavir With Ritonavir in HIV-Infected Patients". The purpose of this clinical research study is to assess the effect of Famotidine given twice daily on Atazanavir administered with Ritonavir in HIV-Infected subjects.
What is the current status of trial NCT00384904?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2006-12. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00384904?
The interventions under investigation include: Atazanavir/Ritonavir (DRUG), Atazanavir/Ritonavir + Famotidine (DRUG), Atazanavir/Ritonavir + Tenofovir Disproxil Fumrarate + Famotidine (DRUG).
Who is sponsoring clinical trial NCT00384904?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.